Neumora Therapeutics Inc. | Small-cap | Healthcare
$1.45
-12.12%
| Neumora Therapeutics Stock Comparison:
Neumora Therapeutics vs VertexNeumora Therapeutics vs RegeneronNeumora Therapeutics vs Harmony BiosciencesNeumora Therapeutics vs Ocular TherapeutixNeumora Therapeutics vs Beam TherapeuticsNeumora Therapeutics vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 0
Operating Income -70.9M
Net Income -68.0M
EPS (Diluted) $-0.42

Balance Sheet Metrics

Total Assets 256.7M
Total Liabilities 28.4M
Shareholders Equity 228.4M
Debt to Equity 0.12

Cash Flow Metrics

Operating Cash Flow -60.8M
Free Cash Flow -59.4M

Revenue & Profitability Trend

Neumora Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i00000
Cost of Goods Sold i-----
Gross Profit i-----
Gross Margin % i0.0%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i200.9M206.6M104.7M212.8M87.1M
Selling, General & Administrative i62.5M45.5M31.1M24.5M8.4M
Other Operating Expenses i-----
Total Operating Expenses i263.5M252.1M135.9M237.3M95.5M
Operating Income i-263.5M-252.1M-135.9M-237.3M-95.5M
Operating Margin % i0.0%0.0%0.0%0.0%0.0%
Non-Operating Items
Interest Income i19.9M16.6M4.6M0-
Interest Expense i-----
Other Non-Operating Income-78.0K-170.0K405.0K11.0K-3.8M
Pre-tax Income i-243.6M-235.7M-130.9M-237.3M-99.3M
Income Tax i178.0K268.0K0--
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-243.8M-235.9M-130.9M-237.3M-99.3M
Net Margin % i0.0%0.0%0.0%0.0%0.0%
Key Metrics
EBITDA i-262.8M-251.4M-135.3M-236.8M-95.4M
EPS (Basic) i-$-3.63$-4.81$-1.56$-0.65
EPS (Diluted) i-$-3.63$-4.81$-1.56$-0.65
Basic Shares Outstanding i-6502100027207000151949096151949096
Diluted Shares Outstanding i-6502100027207000151949096151949096

Income Statement Trend

Neumora Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i142.1M374.0M240.9M409.2M192.0M
Short-term Investments i165.4M79.9M130.9M0-
Accounts Receivable i-----
Inventory i-----
Other Current Assets5.3M----
Total Current Assets i314.1M478.3M388.0M415.6M193.8M
Non-Current Assets
Property, Plant & Equipment i4.6M7.9M10.6M3.8M3.5M
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets-1.2M7.0M2.0M183.0K
Total Non-Current Assets i2.9M17.9M38.3M13.7M4.1M
Total Assets i317.0M496.2M426.2M429.3M197.9M
Liabilities
Current Liabilities
Accounts Payable i3.3M337.0K7.1M1.6M2.4M
Short-term Debt i1.9M3.4M3.4M1.1M764.0K
Current Portion of Long-term Debt-----
Other Current Liabilities133.0K139.0K1.6M1.5M612.0K
Total Current Liabilities i29.9M25.1M23.7M23.3M9.4M
Non-Current Liabilities
Long-term Debt i01.9M5.1M996.0K1.3M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities22.0K155.0K628.0K386.0K-
Total Non-Current Liabilities i22.0K2.0M849.4M731.2M283.0M
Total Liabilities i29.9M27.1M873.1M754.5M292.3M
Equity
Common Stock i16.0K16.0K3.0K3.0K13.0K
Retained Earnings i-947.2M-703.4M-467.5M-336.6M-99.3M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i287.1M469.1M-446.8M-325.2M-94.4M
Key Metrics
Total Debt i1.9M5.2M8.4M2.1M2.0M
Working Capital i284.2M453.2M364.3M392.3M184.5M

Balance Sheet Composition

Neumora Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-243.8M-235.9M-130.9M-237.3M-99.3M
Depreciation & Amortization i631.0K668.0K594.0K538.0K105.0K
Stock-Based Compensation i40.0M17.2M8.3M4.3M1.7M
Working Capital Changes i-505.0K-4.0M-1.7M-5.3M-5.1M
Operating Cash Flow i-200.4M-154.6M-108.4M-79.7M-31.8M
Investing Activities
Capital Expenditures i0-117.0K-511.0K-817.0K-1.3M
Acquisitions i-----
Investment Purchases i-312.2M-109.1M-226.4M0-
Investment Sales i242.4M178.2M71.9M0-
Investing Cash Flow i-70.6M64.4M-168.0M-817.0K-11.2M
Financing Activities
Share Repurchases i0-491.0K00-2.0K
Dividends Paid i-----
Debt Issuance i---055.9M
Debt Repayment i-----
Financing Cash Flow i13.7M229.1M111.5M291.0M230.1M
Free Cash Flow i-182.9M-163.4M-115.4M-76.2M-28.1M
Net Change in Cash i-257.2M138.8M-164.9M210.5M187.0M

Cash Flow Trend

Neumora Therapeutics Key Financial Ratios

Valuation Ratios

Forward P/E -1.07
Price to Book 1.18
PEG Ratio -1.07

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity -79.05%
Return on Assets -48.51%

Financial Health

Current Ratio 8.98
Debt to Equity 0.41

Per Share Data

EPS (TTM) $-1.61
Book Value per Share $1.41

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
nmra269.3M-1.18-79.05%0.00%0.41
Vertex 121.3B32.827.0522.77%31.86%8.89
Regeneron 60.4B14.371.9815.34%31.37%9.04
Harmony Biosciences 2.0B13.132.7424.71%20.50%24.63
Ocular Therapeutix 2.0B-7.40-57.19%91.17%28.66
Beam Therapeutics 1.9B-3.851.59-51.36%0.00%14.08

Financial data is updated regularly. All figures are in the company's reporting currency.